According to media reports, some pharmacies have raised the price of Lianhua Qingwen Capsule to varying degrees. Among them, the price of 0.35g*48 capsules/box increased obviously. There is a drugstore in Heyuan City, Guangdong Province. At present, the price of Lianhua Qingwen Capsule with the specification of 0.35g*48 capsules per box is 46 yuan per box. On the basis of the previous general selling price of about 30 yuan/box, the price will be increased by more than 50%.
Regarding the reasons for the price increase, the report said that some pharmacy staff said, "Recently, the price of Lianhua Qingyi has increased, and many people have bought it recently. The manufacturer's pricing has gone up, and the goods can't be placed. The price must be adjusted. " Some pharmacy employees also said that "the purchase price is expensive."
Then, has Yiling Pharmaceutical, the manufacturer of Lianhua Qingwen, raised the price of related drugs? Is it common for pharmacies to raise prices sharply or even sell flowers to clear the plague?
In this regard, the relevant person in charge of Yiling Pharmaceutical replied to the reporter of Securities Times E Company on the 23rd, saying that "the company has not raised the price of Lianhua Qingyi related drugs".
The reporter of Company E also contacted an instant digital pharmacy head listed company, which has established a 35 1 smart pharmacy network in 7 cities across the country. The relevant person in charge of the company told the reporter that the price of epidemic prevention drugs such as Lianhua Qingyi on the platform has not changed. At present, we haven't heard the news of the price increase of manufacturers. The fluctuation of drug prices in various pharmacies may be due to different promotional activities at different times. "In terms of supply, overall, the supply of drugs such as Lianhua Qingwen on our platform can be guaranteed, and no out-of-stock phenomenon has been found. Sometimes because of the replenishment in the background, we can't place orders at night, and we will also increase procurement and supply. "
Yiling Pharmaceutical issued a statement.
Recently, it is rumored in the market that Lianhua Qingyi Capsule and Lianhua Qingyi Granule are out of stock in some areas, which is also the background of the hot search of "the price increase of pharmacies exceeds 50%".
In response to the rumors of selling out of stock, the relevant person in charge of Yiling Pharmaceutical said in reply to the reporter of E Company that Yiling Pharmaceutical has been doing a series of work to improve production capacity in the past two years. At present, its production capacity has been greatly improved. There are factories producing Lianhua Qingyi products in Shijiazhuang, Beijing, Hengshui and other places, and the current production has basically not been affected. He also said that the production plan of Yiling Pharmaceutical is "fixed production by sales", which can be adjusted in time according to market demand to ensure market supply. Everything is normal in sales at present.
It is worth mentioning that under the background of "out of stock" in some areas such as Lianhua Qingwen, a number of counterfeit "Lianhua" series products have appeared in the market recently. In this regard,165438+1October 22nd, Yiling Pharmaceutical issued a statement saying that there have been many commodities named Lianhua Qingwen tea, Lianhua Qingwen tea, Lianhua Qingwen ointment, Lianhua Qingwen oral liquid, Lianhua Qingwen plant beverage and Lianhua Qingwen pill in the market recently, and these products are not produced, sold or authorized by Yiling Pharmaceutical. Yiling Pharmaceutical said that the above-mentioned products are similar or similar to the brand names and packaging of the company's "Yiling Lianhua Qingfei Tea" (medicine) and its subsidiary's "Lianhua Qingfei Tea" (beverage), which is easy to be confused, and consumers have a great misunderstanding. Yiling Pharmaceutical also mentioned that "Lianhua Qingwen", "Lianhua Qingwen" and "Lianhua Qingfei" are trademarks registered by the company according to law, and they have obtained the exclusive right to use the trademarks, but the design patent of "Lianhua Qingwen Capsule" produced by them is not authorized to be used by others. The company reserves the right to investigate the legal responsibility of the relevant responsible person for the acts that infringe on the legitimate rights and interests of the company's exclusive right to use trademarks, such as producing and selling counterfeit products and confusing the company's products.
The stock price has soared recently.
Yiling Pharmaceutical's main business is the research and development, production and sales of patented innovative Chinese medicine. The series of Lianhua Qingwen products produced and sold by Yiling Pharmaceutical Co., Ltd. have attracted much attention because they have entered the diagnosis and treatment projects in COVID-19 for many times.
It is worth mentioning that as a producer of Lianhua Qingwen, Yiling Pharmaceutical has been continuously sought after by funds in the secondary market recently.
According to market data, the share price of Yiling Pharmaceutical has been rising from 18.8 yuan in less than two months since the end of September. Especially since the beginning of 1 1, with the enlargement of trading volume, Yiling Pharmaceutical has issued two announcements of trading changes due to the continuous surge of its share price, and reached a record high of 48.66 yuan/share at1/. However, the stock price has been adjusted back in the past two trading days, and the latest closing price is 39.99 yuan.
In terms of business performance, in the first three quarters of this year, Yiling Pharmaceutical achieved a total operating income of 7.946 billion yuan, down 2.04% year-on-year; The net profit attributable to the mother141400 million yuan, up by 15.58% year-on-year, and the non-net profit141600 million yuan, up by 20.60% year-on-year; The total operating income in the third quarter was 2.38 billion yuan, up 7.41%year-on-year; The net profit returned to the mother was 366 million yuan, up 40.92% year-on-year, and the non-net profit was 365 million yuan, up 49.32% year-on-year.
From the product point of view, the sales of Lianhua Qingwen and other drugs produced by Yiling Pharmaceutical have increased significantly this year. According to the announcement, in the first three quarters, the income of Tongshenqi, the main product of Yiling Pharmaceutical, decreased slightly compared with 202 1 in the same period, but the cardiovascular and cerebrovascular products gradually picked up from Q3, and the cardiovascular and cerebrovascular products in Q3 achieved a slight year-on-year increase; Lianhua Qingwen is a special product for treating COVID-19, influenza and cold. With a high base of 202 1, its revenue still increased year-on-year.
After the release of the third quarterly report, Yiling Pharmaceutical also attracted many institutional investors' surveys. Talking about Lianhua Qingwen's overseas export, the company said that Lianhua Qingwen has been registered in more than 20 countries and regions and has been approved for listing. This year, Lianhua Qingwen continued the good sales situation last year. In the future, the company will continue to promote the overseas registration and sales of Lianhua Qingwen.